Live Analyst Rating Changes 18416 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Eric Coldwell
BAIRD

Eric Coldwell

Robert W. Baird
Wall Street Analyst
★★★★★
#260
on 13Foresight · ranked by our own returns
70%
Success Rate
+6.7%
Average Return
19 of 27 calls profitable · +3.2% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 70% of Eric Coldwell's ratings turned a profit when each position was held for 1 year — averaging +6.7% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

52 Buy 18 Hold 0 Sell
Eric's Stock Coverage 15 ratings · 2026-08-06
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
AHCO
AdaptHealth
 Aug 05, 2026 BUY Strong Buy
+94.5% avg upside
13 analysts
$10.00
53.89% Upside
 · ·
LH
Labcorp Holdings
 Jul 31, 2026 BUY Strong Buy
-13.8% avg upside
37 analysts
$352.00
12.21% Upside
 +1.5% ·
ICLR
Icon
 Jul 31, 2026 BUY Strong Buy
+15.9% avg upside
26 analysts
$194.00
18.65% Upside
 -1.6% ·
FTRE
Fortrea Holdings Inc.
 Jul 30, 2026 BUY Buy
+10.5% avg upside
12 analysts
$23.00
20.74% Upside
 +0.5% ·
IQV
IQVIA Holdings
 Jul 29, 2026 BUY Strong Buy
+2.9% avg upside
39 analysts
$287.00
21.64% Upside
 -6.1% ·
DGX
Quest Diagnostics
 Jul 24, 2026 HOLD Buy
-22.1% avg upside
34 analysts
$255.00
8.12% Upside
 +3.5% ·
MEDP
Medpace Holdings
 Jul 24, 2026 HOLD Buy
-17.4% avg upside
17 analysts
$624.00
6.14% Upside
 -2.3% ·
MDLN
Medline
 Jun 02, 2026 BUY Strong Buy
+35.7% avg upside
26 analysts
$45.00
22.68% Upside
 +6.0% ·
ACH
Accendra Health
 May 12, 2026 BUY Hold
+487.4% avg upside
17 analysts
$6.00
102.75% Upside
 +4.4% ·
MCK
McKesson
 May 08, 2026 BUY Strong Buy
-16.6% avg upside
28 analysts
$941.00
7.25% Upside
 +19.3% ·
CRL
Charles River Labs
 May 08, 2026 BUY Strong Buy
-13.9% avg upside
34 analysts
$213.00
18.31% Downside
 +47.2% ·
COR
Cencora
 May 07, 2026 BUY Buy
-1.3% avg upside
44 analysts
$339.00
6.83% Upside
 +21.7% ·
CAH
Cardinal Health
 May 01, 2026 BUY Strong Buy
-17.4% avg upside
29 analysts
$248.00
3.59% Upside
 +22.8% ·
CVS
CVS Health
 Apr 18, 2022 HOLD Strong Buy
+5.1% avg upside
39 analysts
$110.00
10.99% Upside
 -24.6% ·
MDRX
Veradigm
 May 09, 2014 BUY Buy
+207.0% avg upside
22 analysts
$22.00
358.33% Upside
 -6.9% ·
🔒 10 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Eric Coldwell — Frequently Asked Questions
How accurate are Eric Coldwell's stock ratings?
Based on the calls 13Foresight could measure, about 74% of Eric's ratings were profitable over a one-year hold, with an average return of +7.0% per rating, or +3.3% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Eric ranked on 13Foresight?
Eric Coldwell is currently ranked #260 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Eric cover?
Eric most recently has ratings on AHCO, LH, ICLR, FTRE, IQV, DGX, MEDP, MDLN, ACH, MCK, CRL, COR and 3 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.